| PubChem CID | Drug (INN) | Original Targets (Gene Symbol) | Original Indications |
|---|---|---|---|
| 5566 | trifluoperazine | ADCY1, ADCY3, ADCY4, ADCY6, ADCY8, ADCY9, ADRA1A, ANXA10, ANXA13, ANXA2, ANXA3, ANXA5, ANXA6, CALM1, CALY, DRD2, DRD4, DRD5, F2, FDPS, GRK7, LTB4R, MYH1, MYH2, MYH4, MYH7B, MYL1, MYL12A, MYL2, MYL7, MYL9, MYLK, MYO15A, MYO18B, MYO1C, MYO1D, MYO1E, MYO3A, MYO3B, MYO5B, MYO5C, NDUFAF3, NDUFS5, S100A4, SLC1A5, SLC5A11, SLC7A5, TNNC1, TNNI3, TNNT2 | Antipsychotic Agents, Antiemetics, Alcoholic Intoxication, Chronic, Bipolar Disorder, Catatonia, Hallucinations, Psychotic Disorders, Schizophrenia, Paranoid Schizophrenia, Brain Injuries, Mental deficiency, Alcoholism, Alcohol abuse, Bipolar disorder, Bipolar I disorder, Hallucination, Psychotic disorder, Schizophrenia, paranoid type, Brain injury |
| Drug Name (INN) |
Predicted Drug Target (Uniprot AC) |
Target Prediction Score (Range: 0~1) |
Binding or Not (Positive binding: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | POLQ (O75417) | 0.139 | 0 | - |
| trifluoperazine | ATP1A2 (P50993) | 0.1385 | 0 | - |
| trifluoperazine | Q61616 | 0.1375 | 0 | - |
| trifluoperazine | SMG6 (Q86US8) | 0.1374 | 0 | - |
| trifluoperazine | CFTR (P13569) | 0.1372 | 0 | - |
| trifluoperazine | STYK1 (Q6J9G0) | 0.1368 | 0 | - |
| trifluoperazine | GPR119 (Q8TDV5) | 0.1367 | 0 | - |
| trifluoperazine | SLC5A6 (Q9Y289) | 0.1366 | 0 | - |
| trifluoperazine | ATM (Q13315) | 0.1364 | 0 | - |
| trifluoperazine | FASN (P49327) | 0.1363 | 0 | - |
| trifluoperazine | PML (P29590) | 0.1363 | 0 | - |
| trifluoperazine | PTPRS (Q13332) | 0.1361 | 0 | - |
| trifluoperazine | AHR (P35869) | 0.1361 | 0 | - |
| trifluoperazine | MAP3K20 (Q9NYL2) | 0.1358 | 0 | - |
| trifluoperazine | Q960X8 | 0.1358 | 0 | - |
| trifluoperazine | SCN1A (P35498) | 0.1355 | 0 | - |
| trifluoperazine | ABCC3 (O15438) | 0.1343 | 0 | - |
| trifluoperazine | DPYD (Q12882) | 0.1343 | 0 | - |
| trifluoperazine | NOS2 (P35228) | 0.1342 | 0 | - |
| trifluoperazine | POLG (P54098) | 0.1341 | 0 | - |
| trifluoperazine | MAP4 (P27816) | 0.1341 | 0 | - |
| trifluoperazine | P08543 | 0.1337 | 0 | - |
| trifluoperazine | CHD1 (O14646) | 0.1335 | 0 | - |
| trifluoperazine | SLC7A9 (P82251) | 0.1334 | 0 | - |
| trifluoperazine | TLR4 (O00206) | 0.133 | 0 | - |
| trifluoperazine | CACNA1E (Q15878) | 0.133 | 0 | - |
| trifluoperazine | RARG (P13631) | 0.1328 | 0 | - |
| trifluoperazine | TLR8 (Q9NR97) | 0.1327 | 0 | - |
| trifluoperazine | SHBG (P04278) | 0.1326 | 0 | - |
| trifluoperazine | ABCC6 (O95255) | 0.1325 | 0 | - |
| trifluoperazine | P11922 | 0.1323 | 0 | - |
| trifluoperazine | PAK3 (O75914) | 0.1322 | 0 | - |
| trifluoperazine | P05041 | 0.132 | 0 | - |
| trifluoperazine | AMOT (Q4VCS5) | 0.1319 | 0 | - |
| trifluoperazine | P04293 | 0.1312 | 0 | - |
| trifluoperazine | PLA1A (Q53H76) | 0.1311 | 0 | - |
| trifluoperazine | GCAT (O75600) | 0.1305 | 0 | - |
| trifluoperazine | IL16 (Q14005) | 0.1305 | 0 | - |
| trifluoperazine | PLA2G6 (O60733) | 0.1304 | 0 | - |
| trifluoperazine | CCR4 (P51679) | 0.1301 | 0 | - |
| trifluoperazine | NISCH (Q9Y2I1) | 0.1298 | 0 | - |
| trifluoperazine | P21932 | 0.1295 | 0 | - |
| trifluoperazine | CASR (P41180) | 0.1292 | 0 | - |
| trifluoperazine | DHCR7 (Q9UBM7) | 0.1292 | 0 | - |
| trifluoperazine | GUCY1A2 (P33402) | 0.1292 | 0 | - |
| trifluoperazine | TRPC4 (Q9UBN4) | 0.1291 | 0 | - |
| trifluoperazine | ABCB1 (P08183) | 0.1291 | 0 | - |
| trifluoperazine | O08532 | 0.129 | 0 | - |
| trifluoperazine | TOP2B (Q02880) | 0.129 | 0 | - |
| trifluoperazine | P26769 | 0.1288 | 0 | - |
| Drug (INN) |
Drug Mechanism (Gene ontology) |
Mechanism Score (Range: 0~1) |
Positive or not (Positive: 1) |
|---|---|---|---|
| trifluoperazine | GO:0006281 DNA repair | 1 | 1 |
| trifluoperazine | GO:0031570 DNA integrity checkpoint | 1 | 1 |
| trifluoperazine | GO:0007049 cell cycle | 0.875 | 1 |
| trifluoperazine | GO:0008283 cell population proliferation (viability) | 0.7 | 1 |
| trifluoperazine | GO:0071456 cellular response to hypoxia | 0.3333 | 0 |
| trifluoperazine | GO:0001525 angiogenesis | 0.2857 | 0 |
| trifluoperazine | GO:0008283 cell population proliferation | 0.25 | 0 |
| trifluoperazine | GO:0006954 inflammatory response | 0.2 | 0 |
| trifluoperazine | GO:0008219 cell death | 0.0625 | 0 |
| trifluoperazine | GO:0006096 glycolytic process | 0 | 0 |
| trifluoperazine | GO:0016477 cell migration | 0 | 0 |
| trifluoperazine | GO:0001837 epithelial to mesenchymal transition | 0 | 0 |
| trifluoperazine | GO:0002418 immune response to tumor cell | 0 | 0 |
| trifluoperazine | GO:0010833 telomere maintenance via telomere lengthening | 0 | 0 |
| trifluoperazine | GO:0001570 vasculogenesis | 0 | 0 |
| trifluoperazine | GO:0007155 cell adhesion | 0 | 0 |
| trifluoperazine | GO:0016049 cell growth | 0 | 0 |
| trifluoperazine | GO:0006915 apoptotic process | 0 | 0 |
| Drug (INN) |
Cancer Type | Indication Score (Range: 0~1) |
Cancer Drug or Not (Positive indication: 1) |
Novel Positives (Novel candidate: 1) |
|---|---|---|---|---|
| trifluoperazine | Cancer(general) | 0.6236 | 0 | - |